Patents by Inventor Antonio Juliá Cano

Antonio Juliá Cano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating rheumatoid arthritis with agents that recognize the B-lymphocyte CD20 membrane receptor
    Patent number: 9845504
    Abstract: An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orf145 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: December 19, 2017
    Assignee: Fundació Institut de Recerca de L'Hospital Universitari Vall D'Hebron
    Inventors: Antonio Juliá Cano, Sara Marsal Barril
  • VITRO METHOD FOR THE PROGNOSIS OR PREDICTION OF THE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH AGENTS THAT RECOGNIZE THE CD20 MEMBRANE RECEPTOR IN B LYMPHOCYTES
    Publication number: 20120225790
    Abstract: An in vitro method for the prognosis or prediction of response in patients with rheumatoid arthritis to treatment with agents recognising the B-lymphocyte CD20 membrane receptor. The method of the invention comprises an assay in a blood sample from these patients and measuring, before starting the treatment, the transcriptional expression level (mRNA) of at least one of the genes selected from the group: ARG1, CPD, TRAF1, C1QA, LRRN3, HLA-DQA1, NLK, TLR4, LOC89944, TOM1L1, BACH, NCALD, EIF2C2, NFIC, PCDHB7, FLJ32770, ARID3A, C14ORF9, CSNK1E, BCAS1, TEAD2, C6orfl45 and SNTA1; and the comparison of this expression level to the expression values previously obtained in patients who responded and who did not respond to the treatment.
    Type: Application
    Filed: June 9, 2010
    Publication date: September 6, 2012
    Applicant: Fundacio Institut de Recerca de L'Hospital Universitari Vall D'Hebron
    Inventors: Antonio Juliá Cano, Sara Marsal Barril